Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 5, 2021
- Accepted in final form April 26, 2021
- First Published July 28, 2021.
Author Disclosures
- Le-Duy Do, PhD* (le-duy.do{at}chu-lyon.fr),
- Christian P. Moritz, PhD* (christian.moritz{at}univ-st-etienne.fr),
- Sergio Muñiz-Castrillo, MD (ext-sergio.muniz{at}chu-lyon.fr),
- Anne-Laurie Pinto, MSc (anne-laurie.pinto{at}chu-lyon.fr),
- Yannick Tholance, PhD (yannick.tholance{at}chu-st-etienne.fr),
- Sabine Brugiere, MSc (sabine.brugiere{at}cea.fr),
- Yohann Couté, PhD (yohann.coute{at}cea.fr),
- Oda Stoevesandt, PhD (oda.stoevesandt{at}pepperprint.com),
- Michael J. Taussig, PhD (mike.taussig{at}cambridgeproteinarrays.com),
- Véronique Rogemond, PhD (veronique.rogemond{at}chu-lyon.fr),
- Alberto Vogrig, MD (alberto.vogrig{at}gmail.com),
- Bastien Joubert, MD, PhD (bastien.joubert{at}chu-lyon.fr),
- Karine Ferraud, MSc (karine.ferraud{at}chu-st-etienne.fr),
- Jean-Philippe Camdessanché, MD, PhD (j.philippe.camdessanche{at}chu-st-etienne.fr),
- Jean-Christophe Antoine, MD, PhD‡ (j.christophe.antoine{at}chu-st-etienne.fr) and
- Jérôme Honnorat, MD, PhD‡
- Le-Duy Do, PhD* (le-duy.do{at}chu-lyon.fr),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Investissements d Avenir? program (reference ANR-18-RHUS-0012) and by ANR-10-INBS-08-01 ProFi and FRM (Fondation pour la Recherche Medicale) DQ20170336751
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Christian P. Moritz, PhD* (christian.moritz{at}univ-st-etienne.fr),
None
NONE
(1) CSL Behring France, Funding for conference travel, (2) German Research Foundation (DFG; MO 3240/1-1:1), Funding for conference travel
NONE
(1) A patent application for anti-Argonaute protein autoantibodies as biomarkers of autoimmune neurological diseases has been submitted.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) French National Research Agency (ANR), ANR-18-RHUS-0012, funding without further involvement in the study, 2020
NONE
(1) German Research Foundation (DFG), MO 3240/1-1:1, (2) Association Francaise contre les Myopathies (AFM-MyoNeurALP), project 6.1.1, (3) Fonds de dotation CSL Behring pour la recherche
NONE
NONE
NONE
NONE
NONE
NONE
- Sergio Muñiz-Castrillo, MD (ext-sergio.muniz{at}chu-lyon.fr),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Anne-Laurie Pinto, MSc (anne-laurie.pinto{at}chu-lyon.fr),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Yannick Tholance, PhD (yannick.tholance{at}chu-st-etienne.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sabine Brugiere, MSc (sabine.brugiere{at}cea.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yohann Couté, PhD (yohann.coute{at}cea.fr),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Oda Stoevesandt, PhD (oda.stoevesandt{at}pepperprint.com),
NONE
NONE
NONE
NONE
NONE
NONE
1) Cambridge Protein Arrays Ltd. CTO Nov 2015 - June 2020 2) PEPperPRINT GmbH Head of Services Aug 2020 - present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael J. Taussig, PhD (mike.taussig{at}cambridgeproteinarrays.com),
NONE
NONE
NONE
New Biotechnology, Editor in Chief
NONE
NONE
Director, Cambridge Protein Arrays Ltd., 10 years.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
As Director of Cambridge Protein Arrays Ltd. I receive annual dividends of c. £8000.
NONE
NONE
NONE
NONE
NONE
- Véronique Rogemond, PhD (veronique.rogemond{at}chu-lyon.fr),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Alberto Vogrig, MD (alberto.vogrig{at}gmail.com),
NONE
NONE
NONE
BMC Neurology, Editorial Board Member, 2020-2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
European Academy of Neurology (EAN)
NONE
NONE
NONE
NONE
NONE
NONE
- Bastien Joubert, MD, PhD (bastien.joubert{at}chu-lyon.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
European Academy of Neurology awarded the following grant: EAN Research Training Fellowship 2019 Institut Servier Research Grant 2020
NONE
NONE
NONE
NONE
NONE
NONE
- Karine Ferraud, MSc (karine.ferraud{at}chu-st-etienne.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jean-Philippe Camdessanché, MD, PhD (j.philippe.camdessanche{at}chu-st-etienne.fr),
None
NONE
Akcea, Alnylam, Biogen, CSL-Behring, Genzyme, Laboratoire Francais des Biotechnologies, Merck-Serono, Novartis, Pfizer, Pharmalliance, Teva, Editions Scientifiques L&C, Edimark, Expression Sante, Natus, Scien, SNF-Floerger. Honoraria.
Associate editor, Revue Neurologique (Paris). No compensation.
Patent on anti-FGFR3 autoantibodies
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jean-Christophe Antoine, MD, PhD‡ (j.christophe.antoine{at}chu-st-etienne.fr) and
Association Française contre les Myopathies
NONE
Pfizer-Travel
NONE
Patents on the use of anti-CRMP5 and anti-FGFR3 antibodies for diagnostic purpose
NONE
NONE
Pfizer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jérôme Honnorat, MD, PhD‡
Scientific advisory board for Bristol Meyers Squibb
NONE
None
NONE
receives royalties from licensing fees to AthenaDiagnostics, Euroimmun, and ravo Diagnostika for a patentfor the use of CV2/CRMP5 as diagnostic tests.
NONE
NONE
NONE
NONE
NONE
NONE
Research support from CSL Behring France
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From French Reference Center on Paraneoplastic Neurological Syndrome (L.-D.D., S.M.-C., A.-L.P., V.R., A.V., B.J., J.-P.C., J.-C.A., J.H.), Hospices Civils de Lyon, Hôpital Neurologique, Bron, France; Institute NeuroMyoGène (L.-D.D., C.P.M., S.M.-C., A.-L.P., Y.T., V.R., A.V., B.J., K.F., J.-P.C., J.-C.A., J.H.), INSERM U1217/CNRS UMR 5310, Université de Lyon, Université Claude Bernard Lyon 1, France; University Jean Monnet (C.P.M., Y.T., J.-P.C., J.-C.A.), Saint-Étienne, France; Department of Biochemistry (Y.T.), University Hospital of Saint-Etienne, France; University Grenoble Alpes (S.B., Y.C.), CEA, INSERM, IRIG, BGE, France; Cambridge Protein Arrays Ltd. (O.S., M.J.T.), Babraham Research Campus, United Kingdom; and Department of Neurology (K.F., J.-P.C., J.-C.A.), University Hospital of Saint-Etienne, France.
- Correspondence
Dr. Honnorat jerome.honnorat{at}chu-lyon.fr
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Updated Diagnostic Criteria for Paraneoplastic Neurologic SyndromesFrancesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo et al.Neurology: Neuroimmunology & Neuroinflammation, May 18, 2021 -
Article
Paraneoplastic MyeloneuropathiesClinical, Oncologic, and Serologic AccompanimentsShailee Shah, Rocio Vazquez Do Campo, Neeraj Kumar et al.Neurology, November 18, 2020 -
Article
Autoimmune gait disturbance accompanying adaptor protein-3B2-IgGJosephe A. Honorat, A. Sebastian Lopez-Chiriboga, Thomas J. Kryzer et al.Neurology, August 01, 2019 -
Article
Thymoma and Autoimmune EncephalitisClinical Manifestations and AntibodiesMar Guasp, Jon Landa, Eugenia Martinez-Hernandez et al.Neurology: Neuroimmunology & Neuroinflammation, July 23, 2021